{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:16:51Z","timestamp":1788239811585,"version":"build-2803163510"},"reference-count":57,"publisher":"Jaypee Brothers Medical Publishing","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.59556\/japi.74.1665","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:26:11Z","timestamp":1788236771000},"page":"81-86","source":"Crossref","is-referenced-by-count":0,"title":["Risk Factors and Emerging Therapies for Immune Checkpoint Inhibitor-related Myocarditis: A Narrative Review"],"prefix":"10.59556","volume":"74","author":[{"given":"Ujjvala","family":"Kalluri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maazen Naduthra","family":"Subair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"issue":"(17):","key":"key20260901042608_B1","doi-asserted-by":"crossref","first-page":"1974\u2013","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy.","volume":"33","author":"Postow","year":"2015;","journal-title":"J Clin Oncol"},{"key":"key20260901042608_B2","doi-asserted-by":"crossref","first-page":"829.","DOI":"10.3389\/fimmu.2017.00829","article-title":"Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models.","volume":"8:","author":"Decker","year":"2017;","journal-title":"Front Immunol"},{"key":"key20260901042608_B3","doi-asserted-by":"crossref","first-page":"147\u2013","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?.","volume":"39:","author":"Fares","year":"2019;","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"key20260901042608_B4","doi-asserted-by":"crossref","first-page":"2965.","DOI":"10.3389\/fimmu.2019.02965","article-title":"The intriguing history of cancer immunotherapy.","volume":"10:","author":"Dobosz","year":"2019;","journal-title":"Front Immunol"},{"key":"key20260901042608_B5","doi-asserted-by":"crossref","first-page":"51\u2013","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors.","volume":"44:","author":"Spain","year":"2016;","journal-title":"Cancer Treat Rev"},{"issue":"(8):","key":"key20260901042608_B6","doi-asserted-by":"crossref","first-page":"879\u2013","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis.","volume":"23","author":"Ganatra","year":"2018;","journal-title":"Oncologist"},{"issue":"(7):","key":"key20260901042608_B7","doi-asserted-by":"crossref","first-page":"1243.","DOI":"10.3390\/diagnostics13071243","article-title":"Immune checkpoint inhibitors-related myocarditis: a review of reported clinical cases.","volume":"13","author":"Zotova","year":"2023;","journal-title":"Diagnostics (Basel)"},{"key":"key20260901042608_B8","doi-asserted-by":"crossref","first-page":"1455347.","DOI":"10.3389\/fimmu.2025.1455347","article-title":"Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review.","volume":"16:","author":"Man","year":"2025;","journal-title":"Front Immunol"},{"issue":"(1):","key":"key20260901042608_B9","doi-asserted-by":"crossref","first-page":"17324.","DOI":"10.1038\/s41598-021-96467-5","article-title":"Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data.","volume":"11","author":"Makunts","year":"2021;","journal-title":"Sci Rep"},{"key":"key20260901042608_B10","doi-asserted-by":"crossref","first-page":"835510.","DOI":"10.3389\/fphar.2022.835510","article-title":"PD-1\/PD-L1 inhibitor-associated myocarditis: epidemiology, characteristics, diagnosis, treatment, and potential mechanism.","volume":"13:","author":"Dong","year":"2022;","journal-title":"Front Pharmacol"},{"issue":"(18):","key":"key20260901042608_B11","doi-asserted-by":"crossref","first-page":"4494.","DOI":"10.3390\/cancers14184494","article-title":"Pathophysiology of immune checkpoint inhibitor-induced myocarditis.","volume":"14","author":"Jim\u00e9nez-Alejandre","year":"2022;","journal-title":"Cancers (Basel)"},{"issue":"(7):","key":"key20260901042608_B12","doi-asserted-by":"crossref","first-page":"753\u2013","DOI":"10.1007\/s11912-023-01414-4","article-title":"Risk factors for immune checkpoint inhibitor-mediated cardiovascular toxicities.","volume":"25","author":"Yousif","year":"2023;","journal-title":"Curr Oncol Rep"},{"issue":"(2):","key":"key20260901042608_B13","doi-asserted-by":"crossref","first-page":"158\u2013","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018;","journal-title":"N Engl J Med"},{"issue":"(11):","key":"key20260901042608_B14","doi-asserted-by":"crossref","first-page":"1904\u2013","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations.","volume":"123","author":"Johnson","year":"2017;","journal-title":"Cancer"},{"issue":"(2):","key":"key20260901042608_B15","doi-asserted-by":"crossref","first-page":"234\u2013","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders.","volume":"2","author":"Johnson","year":"2016;","journal-title":"JAMA Oncol"},{"issue":"(16):","key":"key20260901042608_B16","doi-asserted-by":"crossref","first-page":"1755\u2013","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors.","volume":"71","author":"Mahmood","year":"2018;","journal-title":"J Am Coll Cardiol"},{"issue":"(10):","key":"key20260901042608_B17","doi-asserted-by":"crossref","first-page":"909\u2013","DOI":"10.1177\/00033197231201929","article-title":"Immune-checkpoint inhibitor-related myocarditis: where we are and where we will go.","volume":"75","author":"Vergara","year":"2024;","journal-title":"Angiology"},{"issue":"(18):","key":"key20260901042608_B18","doi-asserted-by":"crossref","first-page":"1749\u2013","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade.","volume":"375","author":"Johnson","year":"2016;","journal-title":"N Engl J Med"},{"issue":"(Suppl 7):","key":"key20260901042608_B19","doi-asserted-by":"crossref","first-page":"vii17\u2013","DOI":"10.1093\/rheumatology\/kez465","article-title":"Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors.","volume":"58","author":"Ibraheim","year":"2019;","journal-title":"Rheumatology (Oxford)"},{"issue":"(4):","key":"key20260901042608_B20","doi-asserted-by":"crossref","first-page":"603.","DOI":"10.3390\/jcm10040603","article-title":"Epidemiological impact of myocarditis.","volume":"10","author":"Golpour","year":"2021;","journal-title":"J Clin Med"},{"issue":"(8):","key":"key20260901042608_B21","doi-asserted-by":"crossref","first-page":"711\u2013","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010;","journal-title":"N Engl J Med"},{"issue":"(4):","key":"key20260901042608_B22","doi-asserted-by":"crossref","first-page":"320\u2013","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation.","volume":"372","author":"Robert","year":"2015;","journal-title":"N Engl J Med"},{"issue":"(1):","key":"key20260901042608_B23","doi-asserted-by":"crossref","first-page":"23\u2013","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015;","journal-title":"N Engl J Med"},{"issue":"(21):","key":"key20260901042608_B24","doi-asserted-by":"crossref","first-page":"2006\u2013","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.","volume":"372","author":"Postow","year":"2015;","journal-title":"N Engl J Med"},{"issue":"(12):","key":"key20260901042608_B25","doi-asserted-by":"crossref","first-page":"1579\u2013","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.","volume":"19","author":"Salem","year":"2018;","journal-title":"Lancet Oncol"},{"issue":"(10):","key":"key20260901042608_B26","doi-asserted-by":"crossref","first-page":"1739\u2013","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.","volume":"23","author":"Rubio-Infante","year":"2021;","journal-title":"Eur J Heart Fail"},{"issue":"(5):","key":"key20260901042608_B27","doi-asserted-by":"crossref","first-page":"1145.","DOI":"10.3390\/cancers14051145","article-title":"Immune checkpoint inhibitors-associated cardiotoxicity.","volume":"14","author":"Li","year":"2022;","journal-title":"Cancers (Basel)"},{"issue":"(20):","key":"key20260901042608_B28","doi-asserted-by":"crossref","first-page":"5218.","DOI":"10.3390\/cancers13205218","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review.","volume":"13","author":"Shalata","year":"2021;","journal-title":"Cancers (Basel)"},{"issue":"(2):","key":"key20260901042608_B29","first-page":"111\u2013","article-title":"Risk factors for immune checkpoint inhibitor-related myocarditis: an integrative review.","volume":"15","author":"Otto","year":"2024;","journal-title":"J Adv Pract Oncol"},{"issue":"(1):","key":"key20260901042608_B30","doi-asserted-by":"crossref","first-page":"7\u2013","DOI":"10.1016\/j.cpcardiol.2012.07.003","article-title":"Sex and gender differences in myocarditis and dilated cardiomyopathy.","volume":"38","author":"Fairweather","year":"2013;","journal-title":"Curr Probl Cardiol"},{"issue":"(1):","key":"key20260901042608_B31","first-page":"3.","article-title":"Cardiotoxicity risk factors with immune checkpoint inhibitors.","volume":"8","author":"Brumberger","year":"2022;","journal-title":"Cardiooncology"},{"issue":"(2):","key":"key20260901042608_B32","doi-asserted-by":"crossref","first-page":"368\u2013","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.","volume":"28","author":"Menzies","year":"2017;","journal-title":"Ann Oncol"},{"issue":"(19):","key":"key20260901042608_B33","doi-asserted-by":"crossref","first-page":"1905\u2013","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders.","volume":"36","author":"Leonardi","year":"2018;","journal-title":"J Clin Oncol"},{"issue":"(9):","key":"key20260901042608_B34","doi-asserted-by":"crossref","first-page":"e447\u2013","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity.","volume":"19","author":"Lyon","year":"2018;","journal-title":"Lancet Oncol"},{"issue":"(12):","key":"key20260901042608_B35","doi-asserted-by":"crossref","first-page":"1920\u2013","DOI":"10.1016\/j.amjcard.2020.02.016","article-title":"Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors.","volume":"125","author":"Oren","year":"2020;","journal-title":"Am J Cardiol"},{"key":"key20260901042608_B36","doi-asserted-by":"crossref","first-page":"882167.","DOI":"10.3389\/fcvm.2022.882167","article-title":"Immune checkpoint inhibitor-associated cardiotoxicity in solid tumors: real-world incidence, risk factors, and prognostic analysis.","volume":"9:","author":"Chen","year":"2022;","journal-title":"Front Cardiovasc Med"},{"issue":"(21):","key":"key20260901042608_B37","doi-asserted-by":"crossref","first-page":"2085\u2013","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity.","volume":"136","author":"Escudier","year":"2017;","journal-title":"Circulation"},{"issue":"(7):","key":"key20260901042608_B38","doi-asserted-by":"crossref","first-page":"743\u2013","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution.","volume":"138","author":"Anquetil","year":"2018;","journal-title":"Circulation"},{"issue":"(8):","key":"key20260901042608_B39","doi-asserted-by":"crossref","first-page":"102586.","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.","volume":"19","author":"Allenbach","year":"2020;","journal-title":"Autoimmun Rev"},{"issue":"(5):","key":"key20260901042608_B40","doi-asserted-by":"crossref","first-page":"e145186.","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.","volume":"131","author":"Moslehi","year":"2021;","journal-title":"J Clin Invest"},{"issue":"(33):","key":"key20260901042608_B41","doi-asserted-by":"crossref","first-page":"2636\u2013","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.","volume":"34","author":"Caforio","year":"2013;","journal-title":"Eur Heart J"},{"issue":"(24):","key":"key20260901042608_B42","doi-asserted-by":"crossref","first-page":"3158\u2013","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations.","volume":"72","author":"Ferreira","year":"2018;","journal-title":"J Am Coll Cardiol"},{"issue":"(12):","key":"key20260901042608_B43","doi-asserted-by":"crossref","first-page":"1503\u2013","DOI":"10.1016\/j.jacc.2021.01.050","article-title":"Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor-associated myocarditis.","volume":"77","author":"Thavendiranathan","year":"2021;","journal-title":"J Am Coll Cardiol"},{"issue":"(3):","key":"key20260901042608_B44","doi-asserted-by":"crossref","first-page":"512\u2013","DOI":"10.1148\/radiol.211765","article-title":"Cardiac MRI features and prognostic value in immune checkpoint inhibitor-induced myocarditis.","volume":"303","author":"Cadour","year":"2022;","journal-title":"Radiology"},{"issue":"(8):","key":"key20260901042608_B45","doi-asserted-by":"crossref","first-page":"1205\u2013","DOI":"10.2169\/internalmedicine.4162-24","article-title":"Effectiveness of additional immunosuppressive drugs for corticosteroid-refractory immune checkpoint inhibitor-induced myocarditis: two case reports.","volume":"64","author":"Sakaguchi","year":"2025;","journal-title":"Intern Med"},{"issue":"(4):","key":"key20260901042608_B46","doi-asserted-by":"crossref","first-page":"391\u2013","DOI":"10.1016\/j.jacc.2024.10.080","article-title":"2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis: a report of the American College of Cardiology Solution Set Oversight Committee.","volume":"85","author":"Drazner","year":"2025;","journal-title":"J Am Coll Cardiol"},{"issue":"(3):","key":"key20260901042608_B47","doi-asserted-by":"crossref","first-page":"285\u2013","DOI":"10.1093\/ajhp\/54.3.285","article-title":"Mycophenolate mofetil: a unique immunosuppressive agent.","volume":"54","author":"Hood","year":"1997;","journal-title":"Am J Health Syst Pharm"},{"issue":"(15):","key":"key20260901042608_B48","doi-asserted-by":"crossref","first-page":"4913.","DOI":"10.3390\/jcm12154913","article-title":"Comparative efficacy and safety of mycophenolate mofetil and azathioprine in combination with corticosteroids in the treatment of lymphocytic myocarditis.","volume":"12","author":"Blagova","year":"2023;","journal-title":"J Clin Med"},{"issue":"(6):","key":"key20260901042608_B49","first-page":"e69\u2013","article-title":"Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association.","volume":"141","author":"Kociol","year":"2020;","journal-title":"Circulation"},{"issue":"(7):","key":"key20260901042608_B50","doi-asserted-by":"crossref","first-page":"921\u2013","DOI":"10.1038\/bjc.2017.253","article-title":"Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.","volume":"117","author":"Tay","year":"2017;","journal-title":"Br J Cancer"},{"issue":"(4):","key":"key20260901042608_B51","doi-asserted-by":"crossref","first-page":"424\u2013","DOI":"10.1016\/j.amjms.2021.04.018","article-title":"Successful treatment of steroid-refractory checkpoint inhibitor myocarditis with globulin derived-therapy: a case report and literature review.","volume":"362","author":"Barry","year":"2021;","journal-title":"Am J Med Sci"},{"issue":"(5):","key":"key20260901042608_B52","doi-asserted-by":"crossref","first-page":"800\u2013","DOI":"10.1016\/j.jaccao.2020.10.013","article-title":"Immune checkpoint inhibitor-associated myocarditis with persistent troponin elevation despite abatacept and prolonged immunosuppression.","volume":"2","author":"Liu","year":"2020;","journal-title":"JACC CardioOncol"},{"key":"key20260901042608_B53","doi-asserted-by":"crossref","first-page":"922782.","DOI":"10.3389\/fimmu.2022.922782","article-title":"TNF-\u03b1 inhibitors and other biologic agents for the treatment of immune checkpoint inhibitor-induced myocarditis.","volume":"13:","author":"Liu","year":"2022;","journal-title":"Front Immunol"},{"issue":"(16_suppl):","key":"key20260901042608_B54","doi-asserted-by":"crossref","first-page":"TPS2680.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2680","article-title":"Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): phase 3, investigator-initiated, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept compared to placebo in hospitalized patients with immune checkpoint inhibitor associated myocarditis.","volume":"41","author":"Reynolds","year":"2023;","journal-title":"J Clin Oncol"},{"issue":"(1):","key":"key20260901042608_B55","first-page":"15.","article-title":"Refractory right ventricular myocarditis induced by immune checkpoint inhibitor despite therapy cessation and immune suppression.","volume":"9","author":"Mohammad","year":"2023;","journal-title":"Cardiooncology"},{"issue":"(23):","key":"key20260901042608_B56","doi-asserted-by":"crossref","first-page":"1885\u2013","DOI":"10.1161\/CIRCULATIONAHA.119.043171","article-title":"Heart-specific immune responses in an animal model of autoimmune-related myocarditis mitigated by an immunoproteasome inhibitor and genetic ablation.","volume":"141","author":"Bockstahler","year":"2020;","journal-title":"Circulation"},{"issue":"(12):","key":"key20260901042608_B57","doi-asserted-by":"crossref","first-page":"1442\u2013","DOI":"10.1093\/cvr\/cvae133","article-title":"Central memory CD4+ T cells play a protective role against immune checkpoint inhibitor-associated myocarditis.","volume":"120","author":"Yu","year":"2024;","journal-title":"Cardiovasc Res"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:26:20Z","timestamp":1788236780000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-8-81"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.59556\/japi.74.1665"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1665","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}